Partnering for innovative stroke treatments: Interview with Liz Dallimore, CEO of Argenica Therapeutics

Progress: NaN%
Current Time 0:00
Duration Time 0:00

Partnering for innovative stroke treatments: Interview with Liz Dallimore, CEO of Argenica Therapeutics

About the speakers
  • Dr Tina Soulis has over 27 years of working in the healthcare (pharmaceuticals and devices), biotechnology, academic research, clinical research and management sectors in senior roles including: CEO of a Contract Research Organization, Director of a successful ASX200 company, VP of Clinical Strategy and Development with an innovative biotechnology company and now, Founder and Director of her own clinical consultancy company. A dynamic and strategic leader, Tina has an extensive network of stakeholders all over the world and experience in many therapeutic areas across all phases on development. Tina holds academic appointments with: * University of Melbourne (teaching and supporting undergraduate pharmacology, Masters in Leadership in Science and Master in Commercialization in Science students) Passionate about mentoring future industry leaders and advocating for the Australian R&D community, Tina serves on several therapeutics executive advisory boards and advisors many US-based biotechnology companies including: - MiNDAUS - Australian Neimann Pick-Type C Disease Foundation -National Imaging Facility -AusBiotech ABCTag clinical trials executive committee Tina is a regular invited speaker locally and globally on a broad range of topics on Clinical trials, Research, Innovation and Industry Collaboration. Recently, Tina launched her own consultancy, Alithia Life Sciences, where her motivation and mission is to work with her clients to deliver efficient accomplishment of their project, add value to their programs and to ultimately enable improvement of human health and wellbeing. Being strategic advisor to Neuroscience Trials Australia (NTA), a world-leading Contract Research Organization (CRO) specializing in all aspects of (neuroscience) clinical development also keeps Tina inspired about new products being developed. Focused on delivering global standard clinical trial projects for pharmaceutical, biotechnology and device clients, this CRO aims to create value for clients. When Tina was CEO for NTA, she successfully grew the business on average 39% annually, thus forming a sustainable and world-respected organization. Tina is one of the few Australian clinical development leaders who has successfully taken products from lab to regulatory approval.
  • Dr Liz Dallimore
    Dr Liz Dallimore
    CEO & Managing Director at Argenica Therapeutics
    Liz is a research & development, innovation and commercialisation specialist. She is currently Managing Director and CEO of Argenica Therapeutics (ASX:AGN), an early stage biotechnology company developing novel neuroprotective therapeutics for stroke and other types of brain injury, and co-founder and Chair of medical device start-up Inspiring Holdings. Liz is passionate about the life sciences industry and an dedicated advocate for building life science and STEM capability in Australia.

Key takeaways

Partnering is crucial for running acute trials in emergency departments successfully.

A good fit ensures smooth communication, efficient teamwork, and a proactive approach to getting things done.

Establishing trust and rapport with Principal Investigators and clinicians is crucial for successful clinical trials.